BioNxt Solutions to Acquire IP for Sublingual Chemotherapy Drug

BioNxt Solutions Inc., a bioscience innovator in advanced drug delivery systems, has signed a letter agreement with a European chemotherapy company. The agreement grants BioNxt exclusive intellectual property rights to a novel sublingual drug formulation. This formulation is designed for oncology and immunosuppressant treatments.

The project will involve prototype development, IP filings, preclinical and clinical studies, and regulatory filings. BioNxt will hold 100% of the intellectual property rights, while the Codeveloper receives a 20% royalty on third-party license fees, capped at USD 50 million. A definitive agreement is anticipated within 60 days.

The immunosuppressant market is projected to grow significantly, expected to reach USD 61.05 billion globally by 2025 according to Statista. This move is part of BioNxt's strategy to enhance its intellectual property portfolio and expand its product pipeline.